The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Open accessAbstract
Flaviviruses, including dengue and Zika viruses, are of substantial public health concern. Klein and colleagues review the development of broad-spectrum antiviral agents that would target many of the known and potentially unknown flaviviruses. The benefits and caveats of molecules that target either viral proteins or host mechanisms exploited by these viruses are discussed. Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk. This Review summarizes and comments on the opportunities for broad-spectrum agents that are active against multiple flaviviruses. Broad-spectrum activity is particularly desirable to prepare for the next flaviviral epidemic, which could emerge from as-yet unknown or neglected viruses. Potential molecular targets for broad-spectrum antiflaviviral compounds include viral proteins, such as the viral protease or polymerase, and host targets that are exploited by these viruses during entry and replication, including α-glucosidase and proteins involved in nucleoside biosynthesis. Numerous compounds with broad-spectrum antiviral activity have already been identified by target-specific or phenotypic assays. For other compounds, broad-spectrum activity can be anticipated because of their mode of action and molecular targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–245 of 245
Magnetic resonance imaging findings in Guillain-Barré syndrome caused by Zika virus infection
Fontes, C. A. P., dos Santos, A. A. S. M. D., & Marchiori, E. D. S. (2016) · Neuroradiology · doi:10.1007/s00234-016-1687-9 · Cited by 71
Dengue virus capsid protein interacts specifically with very low-density lipoproteins
Faustino, A. F., Carvalho, F. A., Martins, I. C., Castanho, M. A. R. B., Mohana‐Borges, R., Almeida, F. C. L., Poian, A. T. D., & Santos, N. C. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.06.004 · Cited by 70
Behnam, M. A. M., Nitsche, C., Vechi, S. M., & Klein, C. D. P. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500245v · Cited by 69
Self-citationYeo, K. L., Chen, Y., Xu, H. Y., Dong, H., Wang, Q.-Y., Yokokawa, F., & Shi, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04779-14 · Cited by 68
An Animal Model for the Tickborne Flavivirus—Omsk Hemorrhagic Fever Virus
Holbrook, M. R., Aronson, J. F., Campbell, G. A., Jones, S. J. M., Feldmann, H., & Barrett, A. D. T. (2004) · The Journal of Infectious Diseases · doi:10.1086/426397 · Cited by 68
Host sphingomyelin increases West Nile virus infection in vivo
Martín-Acebes, M. A., Gabandé‐Rodríguez, E., García-Cabrero, A. M., Sánchez, M. P., Ledesma, M. D., Sobrino, F., & Sáiz, J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m064212 · Cited by 67
Brecher, M. B., Chen, H., Li, Z., Banavali, N. K., Jones, S. A., Zhang, J., Kramer, L. D., & Li, H. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00070 · Cited by 65
AVI-7288 for Marburg Virus in Nonhuman Primates and Humans
Heald, A. E., Charleston, J. S., Iversen, P. L., Warren, T. K., Saoud, J. B., Al-Ibrahim, M. S., Wells, J., Warfield, K. L., Swenson, D. L., Welch, L. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410345 · Cited by 63
Zhao, X., Guo, F., Comunale, M. A., Mehta, A. S., Sehgal, M., Jain, P., Cuconati, A., Lin, H., Block, T. M., Chang, J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03999-14 · Cited by 63
Dengue Virus Evolution under a Host-Targeted Antiviral
Plummer, E. M., Buck, M. D., Sanchez, M., Greenbaum, J., Turner, J., Grewal, R., Klose, B., Sampath, A., Warfield, K. L., Peters, B., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00028-15 · Cited by 63
Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase
Sweeney, N. L., Hanson, A. M., Mukherjee, S., Ndjomou, J., Geiss, B. J., Steel, J. J., Frankowski, K. J., Li, K., Schoenen, F. J., & Frick, D. N. (2015) · ACS Infectious Diseases · doi:10.1021/id5000458 · Cited by 63
Gu, B., Mason, P. W., Wang, L., Norton, P. A., Bourne, N., Moriarty, R. M., Mehta, A. S., Despande, M., Shah, R., & Block, T. M. (2007) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020701800105 · Cited by 60
The Bioactive Lipid 4-Hydroxyphenyl Retinamide Inhibits Flavivirus Replication
Carocci, M., Hinshaw, S. M., Rodgers, M. A., Villareal, V. A., Burri, D. J., Pilankatta, R., Maharaj, N. P., Gack, M. U., Stavale, E. J., Warfield, K. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04177-14 · Cited by 60
Yu, W., Gill, T., Wang, L., Du, Y., Ye, H., Qu, X., Guo, J., Cuconati, A., Zhao, K., Block, T. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300171v · Cited by 59
Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection
Choy, M. M. J., Zhang, S. L.-X., Costa, V. V., Tan, H. C., Horrevorts, S. K., & Ooi, E. E. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004058 · Cited by 59
Dengue virus requires the CC‐chemokine receptor CCR5 for replication and infection development
Marques, R. E., Guabiraba, R., Sarto, J. L. D., Rocha, R. D. P. F., Queiroz, A. L. L., Cisalpino, D., Marques, P. E., Pacca, C. C., Fagundes, C. T., Menezes, G. B., et al. (2015) · Immunology · doi:10.1111/imm.12476 · Cited by 58
Saudi, M., Żmurko, J., Kaptein, S. J. F., Rozenski, J., Neyts, J. H., & Aerschot, A. A. V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.062 · Cited by 58
Utility of Humanized BLT Mice for Analysis of Dengue Virus Infection and Antiviral Drug Testing
Frias‐Staheli, N., Dorner, M., Marukian, S., Billerbeck, E., Labitt, R. N., Rice, C. M., & Ploß, A. (2013) · Journal of Virology · doi:10.1128/jvi.03085-13 · Cited by 58
Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication
Trabattoni, D., Gnudi, F., Ibba, S. V., Saulle, I., Agostini, S., Masetti, M., Biasin, M., Rossignol, J., & Clerici, M. (2016) · Scientific Reports · doi:10.1038/srep27148 · Cited by 55
Smith, J. L., Stein, D. A., Shum, D., Fischer, M. A., Radu, C., Bhinder, B., Djaballah, H., Nelson, J. A., Früh, K., & Hirsch, A. J. (2014) · Journal of Virology · doi:10.1128/jvi.00365-14 · Cited by 50
Idris, F., Muharram, S. H., & Diah, S. (2016) · Archives of Virology · doi:10.1007/s00705-016-2855-2 · Cited by 50
Kim, M. Y., Shu, Y., Carsillo, T., Zhang, J., Yu, L., Peterson, C., Longhi, S., Girod, S., Niewiesk, S., & Oglesbee, M. (2012) · Journal of Virology · doi:10.1128/jvi.02710-12 · Cited by 49
Gupta, G., Lim, L., & Song, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134823 · Cited by 48
Munier‐Lehmann, H., Lucas‐Hourani, M., Guillou, S., Helynck, O., Zanghì, G., Noël, A., Tangy, F., Vidalain, P., & Janin, Y. L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501446r · Cited by 48
Lima, A. B., Behnam, M. A. M., Sherif, Y. E., Nitsche, C., Vechi, S. M., & Klein, C. D. P. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.012 · Cited by 47
Self-citationA Novel Model for the Study of the Therapy of Flavivirus Infections Using the Modoc Virus
Leyssen, P., Lommel, A. V., Drosten, C., SCHMITZ, H. E., Clercq, E. D., & Neyts, J. H. (2001) · Virology · doi:10.1006/viro.2000.0723 · Cited by 47
Ando, T., Kojima, K., Isoda, H., Eguchi, Y., Honda, T., Ishigami, M., & Kimura, S. H. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1788-y · Cited by 44
Product review on the JE vaccine IXIARO
Firbas, C., & Jilma, B. (2015) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.983412 · Cited by 44
Kumar, M., Rawat, P., Khan, S. Z., Dhamija, N., Chaudhary, P., Ravi, D. S., & Mitra, D. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.005 · Cited by 44
Thibodeaux, B. A., Garbino, N. C., Liss, N. M., Piper, J., Blair, C. D., & Roehrig, J. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.003 · Cited by 44
Nelson, J., Roe, K., Orillo, B., Shi, P., & Verma, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.07.008 · Cited by 43
Bhakat, S., Delang, L., Kaptein, S. J. F., Neyts, J. H., Leyssen, P., & Jayaprakash, V. (2015) · RSC Advances · doi:10.1039/c5ra14469h · Cited by 42
DDX 3 functions in antiviral innate immunity through translational control of PACT
Lai, M., Sun, H. S., Wang, S., & Tarn, W. (2015) · FEBS Journal · doi:10.1111/febs.13553 · Cited by 41
Meanwell, N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00915 · Cited by 40
Larena, M., Regner, M., & Lobigs, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044834 · Cited by 38
First, M. R. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90046-9 · Cited by 33
Warren, T. K., Whitehouse, C. A., Wells, J., Welch, L. S., Charleston, J. S., Heald, A., Nichols, D. K., Mattix, M. E., Palacios, G. F., Kugleman, J. R., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004456 · Cited by 31
Fraser, J. E., Wang, C., Chan, K. W. K., Vasudevan, S. G., & Jans, D. A. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.03.006 · Cited by 30
Stavale, E. J., Vu, H., Sampath, A., Ramstedt, U., & Warfield, K. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121662 · Cited by 29
Lactimidomycin is a broad-spectrum inhibitor of dengue and other RNA viruses
Carocci, M., & Yang, P. L. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.02.005 · Cited by 28
Raaben, M., Grinwis, G. C. M., Rottier, P. J. M., & de Haan, C. A. M. (2010) · Journal of Virology · doi:10.1128/jvi.00486-10 · Cited by 26
Lee, Y., Huang, K., Lei, H.-Y., Chen, S., Lin, Y.-S., Yeh, T., & Liu, H. (2005) · Intervirology · doi:10.1159/000081744 · Cited by 23
The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?
Mondelli, M. U. (2014) · Hepatology · doi:10.1002/hep.27186 · Cited by 23
Vasilakis, N., Falvey, D. A., Gangolli, S., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt845 · Cited by 16
Self-citationLong‐term outcomes of Murray Valley encephalitis cases in Western Australia: what have we learnt?
Selvey, L. A., Speers, D. J., & Smith, D. W. (2015) · Internal Medicine Journal · doi:10.1111/imj.12962 · Cited by 11
Cited by
Ruzek, D., Avšič Županc, T., Borde, J., Chrdle, A., Eyer, L., Karganova, G., Kholodilov, I., Knap, N., Kozlovskaya, L., Matveev, A., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.01.014 · Cited by 414
Rajter, J. C., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J.-J. (2021) · Chest · doi:10.1016/j.chest.2020.10.009 · Cited by 318
The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design
Rey, F. A., Stiasny, K., Vaney, M., Dellarole, M., & Heinz, F. X. (2018) · EMBO reports · doi:10.15252/embr.201745302 · Cited by 259
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
Metadata
- Authors
- Boldescu, V., Behnam, M. A. M., Vasilakis, N., & Klein, C. D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-05-05
- Volume
- 16
- Issue
- 8
- Pages
- 565-586
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2610396252
- Cited by
- 305
- References
- 245
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.